Reuters logo
AbbVie profit beats estimates on higher Humira sales
2015年1月30日 / 下午1点07分 / 3 年前

AbbVie profit beats estimates on higher Humira sales

Jan 30 (Reuters) - U.S. drugmaker AbbVie Inc reported a better-than-expected quarterly adjusted profit due to higher sales of its autoimmune disease drug Humira.

The company reported a net loss of $810 million, or 51 cents per share, in the fourth quarter due to a charge from calling off a $55 billion deal to buy British drugmaker Shire Plc .

Excluding special items, AbbVie earned 89 cents per share. Analysts on average had expected 86 cents per share, according to Thomson Reuters I/B/E/S. (Reporting by Ransdell Pierson; Editing by Don Sebastian)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below